Jinhai International Group Holdings Limited (HK:2225) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jinhai Medical Technology Limited has entered into a master sales agreement with Sinopharm Holdings Lingshang Hospital Management Services, which will serve as the exclusive distributor of Jinhai’s high-end medical devices in China until October 2025. This partnership aims to leverage Sinopharm’s extensive distribution network to enhance Jinhai’s market presence and boost growth in the medical industry. With products like 4K3D fluorescent endoscopes showing strong potential, the company anticipates this collaboration will significantly expand market share and enhance shareholder returns.
For further insights into HK:2225 stock, check out TipRanks’ Stock Analysis page.